AKBA - Akebia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.49
-0.29 (-3.73%)
At close: 4:00PM EST

7.49 0.00 (0.00%)
After hours: 6:51PM EST

Stock chart is not supported by your current browser
Previous Close7.78
Open7.76
Bid7.36 x 1000
Ask10.50 x 800
Day's Range7.29 - 7.93
52 Week Range7.29 - 16.43
Volume562,278
Avg. Volume502,630
Market Cap427.373M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-1.37
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.63
Trade prices are not sourced from all markets
  • David Abrams Buys 3 Stocks in 3rd Quarter
    GuruFocus.com11 hours ago

    David Abrams Buys 3 Stocks in 3rd Quarter

    David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, released his third-quarter portfolio last week, listing three new holdings. Warning! GuruFocus has detected 7 Warning Signs with SHPG.

  • Business Wireyesterday

    Akebia Therapeutics Sends Letter to Shareholders

    Akebia Therapeutics, Inc. (AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”) that has been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx Biopharmaceuticals. The Akebia Board of Directors unanimously recommends that Akebia shareholders vote “FOR” the proposals relating to the proposed merger with Keryx. The Special Meeting to approve our proposed merger with Keryx is approaching.

  • Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 days ago

    Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

    Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 days ago

    Akebia Therapeutics: 3Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire6 days ago

    Akebia Therapeutics Announces Third Quarter 2018 Financial Results

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. “In the third quarter, we continued to drive our vadadustat Phase 3 development program, while working diligently to close our proposed merger transaction with Keryx Biopharmaceuticals by the end of 2018. The combination is expected to create a fully-integrated kidney disease therapeutics company, with a strengthened financial profile, positioned to deliver substantial long-term value to shareholders,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics.

  • Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
    Zacks7 days ago

    Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for

    Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire12 days ago

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Akebia’s common stock on October 31, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $7.49 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
    Business Wire15 days ago

    Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals

    Akebia Therapeutics, Inc. (AKBA) today announced that it and Keryx Biopharmaceuticals, Inc. (KERX) filed a definitive joint proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with their respective special meetings of shareholders that have been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx. Akebia is mailing a letter together with its proxy materials to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”).

  • GlobeNewswire15 days ago

    Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that it and Akebia Therapeutics, Inc. (AKBA) have filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with their respective Special Meetings of Stockholders that have been called to approve the previously announced proposed merger of Keryx and Akebia. The definitive joint proxy statement is available on the Investor Relations section of Keryx’s website, as well as www.sec.gov, and will be mailed to all Keryx common stockholders entitled to vote at the Special Meeting.

  • GlobeNewswire27 days ago

    Report: Developing Opportunities within VICI Properties, Transocean, Akebia Therapeutics, Welltower, Golden Star Resources, and Casa — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wirelast month

    Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced two posters to be presented at the upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California, from October 23 to 28, 2018.

  • Business Wirelast month

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $8.83 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
    Zackslast month

    Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error

    Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.

  • Business Wire2 months ago

    Akebia Therapeutics to Participate in Upcoming Investor Conferences

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-indu

  • Simply Wall St.2 months ago

    What Investors Should Know About Akebia Therapeutics Inc’s (NASDAQ:AKBA) Financial Strength

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Akebia Therapeutics Inc (NASDAQ:AKBA), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • Business Wire2 months ago

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia’s common stock on August 31, 2018, as inducements material to such employee’s entering into employment with Akebia. The options have an exercise price of $8.21 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • Business Wire2 months ago

    Akebia Therapeutics to Participate in Upcoming Investor Conferences

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced that John P.

  • 5 Healthcare Stocks That Are Down, But Not Out!
    InvestorPlace3 months ago

    5 Healthcare Stocks That Are Down, But Not Out!

    Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.

  • Business Wire3 months ago

    Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors. Cynthia Smith has more than 20 years of broad leadership experience within the healthcare industry.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AKBA earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 Akebia Therapeutics Inc Earnings Call

  • Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
    Zacks3 months ago

    Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

    Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...

  • Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

    Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Akebia Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 60 cents. The kidney disease treatment developer posted revenue of $48.8 million in the period. Akebia Therapeutics ...